Sanofi: FDA lifts clinical hold on fitusiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
BofA/Merrill Lynch Remains Sidelined on Sanofi (SNY) Following R&D Meeting
December 18, 2017 9:20 AM ESTBofA/Merrill Lynch reiterates a Neutral rating and $49.00 price target on Sanofi (NYSE: SNY) following the company's R&D Q&A session.
Although Sanofi suggested its PIII lung program for cemiplimab has PFS as a primary endpoint, it clarified today that the... More
